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Abstract 
Context: Conversion to mammalian target of rapamycin inhibitors (mTORi) is often utilised 
in liver transplantation to overcome calcineurin inhibitor (CNI) nephrotoxicity but the 
evidence base for this approach is not well defined. 
Objective: To summarise the evidence, from randomised-clinical-trials (RCTs), for 
conversion from CNI to mTORi-based immunosuppression after liver transplantation. 
Data Sources: Databases and conference abstracts were searched up to August 2015. 
Study Selection: RCTs evaluating conversion from CNI to mTORi-based maintenance 
immunosuppression following adult liver transplantation. 
Data Extraction: Descriptive and quantitative information was extracted; summary mean 
difference (MD) and risk ratio (RR) estimates were synthesized under a random-effects 
model. Heterogeneity was assessed using the Q statistic and I2. 
Data synthesis: Ten RCTs, with a total of 1,927 patients, met the final inclusion criteria. 
Patients converted to mTORi had significantly better renal function at 1 year following 
randomisation compared to patients remaining on CNI (MD: 7.48 mL/min/1.73m2, 95%CI: 
3.18-11.8). The risks of graft loss (RR: 0.77, 95%CI: 0.29-2.09, I2: 31%) and patient death 
(RR: 1.05, 95%CI: 0.63-1.73, I2: 0%) were similar for patients converted to mTORi and 
patients remaining on CNI. However, conversion to mTORi was associated with a higher risk 
of acute rejection (RR: 1.76, 95%CI: 1.33-2.34, I2: 0%) and study discontinuation due to 
adverse events (RR: 2.17, 95%CI: 1.38-3.44, I2: 63%) up to one year post-randomisation. 
Conclusions: Conversion from CNI to mTORi following liver transplantation is associated 
with improved renal function after one year but increases the risk of acute rejection and may 
be poorly tolerated. 
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Introduction 
The calcineurin inhibitors (CNIs) tacrolimus and ciclosporin are the principal components of 
maintenance immunosuppressive therapy following orthotopic liver transplantation and have 
made a major contribution to current long term transplant outcomes with 5-year graft survival 
approaching 70% (1, 2). However, CNIs are associated with a number of potentially serious 
side effects including nephrotoxicity, diabetes, hypertension, and neurotoxicity that 
contribute to morbidity and mortality following transplantation. Renal impairment is a 
particular problem following liver transplantation, with 10-20% of recipients progressing to 
stage 4 or 5 chronic kidney disease within 5 years of transplantation, with CNI therapy being 
a major contributing factor (3-5). 
Mammalian target of Rapamycin inhibitors (mTORi) are a distinct class of 
immunosuppressive agents that have a different mode of action to that of CNIs although they 
bind to the same intracellular immunophilin as tacrolimus, namely FKBP12. The 
mTORi/FKBP12 complex binds to and inhibits the TORC1 complex, inhibiting proliferation 
of many cell types, including lymphocytes (6). The mTORi include sirolimus and the more 
recently introduced sirolimus analogue, everolimus, designed with the aim of improving oral 
bioavailability (7). The side effect profile of mTORi is different to that of CNI and includes 
impaired wound healing, mouth ulcers, skin rashes, arthralgia, diabetes, hyperlipidaemia and 
pneumonitis (8). Importantly mTORi do not share the same nephrotoxicity as CNIs which 
makes them an attractive alternative to CNIs for maintenance therapy after liver 
transplantation; although they do cause glomerular disease in some patients resulting in 
marked proteinuria (9). De novo use of mTORi after liver transplantation is avoided because 
of concerns relating to hepatic artery thrombosis and poor wound healing (10). Interest has 
focussed, instead, on the delayed introduction of mTORi to allow reduction or elimination of 
CNIs to preserve or improve renal function while maintaining adequate levels of 
immunosuppression. A number of randomised controlled trials (RCTs) have examined the 
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potential benefits of introducing either sirolimus or everolimus after liver transplantation 
using a variety of protocols that differ with respect to the timing of conversion to mTORi, 
whether CNI are eliminated or reduced and in the level of baseline renal function at the time 
of mTORi introduction. Such studies have given conflicting results on the efficacy and side 
effect profile of mTORi, but have led to an increasing recognition that mTORi have a 
potentially important role to play in preserving renal function after liver transplantation. 
We have undertaken a systematic review and meta-analysis of randomised trials to assess the 
evidence base for conversion from CNI to mTORi-based maintenance immunosuppression 
after liver transplantation with a particular focus on preservation of renal function. 
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METHODS 
Eligibility criteria, information sources and search strategy 
A systematic literature search was performed using PubMed, EMBASE, the Cochrane 
Central Register of Controlled Trials and the Transplant Library at the Royal College of 
Surgeons of England (RCSEng) up to August 2015 using a predefined algorithm (Table S1) 
without language restrictions. Abstracts from conferences were searched for relevant 
publications using the algorithm implemented in the Transplant Library of the RCSEng (11). 
References included in pertinent systematic reviews were also screened. 
All randomized controlled trials evaluating conversion from CNI to mTORi-based 
maintenance immunosuppression in adult isolated liver transplantation were considered. 
Studies were deemed eligible if they evaluated abrupt or slow conversion to mTORi, in first 
or subsequent liver transplant recipients, irrespective of time after transplantation and 
baseline renal function. Studies that were considered eligible included those where the 
intervention (conversion to mTORi) and reference (CNI continuation) groups received 
additional maintenance immunosuppression comprising antimetabolites (mycophenolate or 
azathioprine) and steroids. Observational and non-controlled studies, studies evaluating 
paediatric patients and animal studies were excluded (Figure 1). Detailed methodology on 
data extraction, on data synthesis and statistical analyses, and on assessment of trial 
methodological quality is presented as supplementary information. Analyses were performed 
in RevMan 5 (Cochrane Collaboration, 2010) and STATA 10 (STATA Corp., College 
Station, IL). All p-values are two tailed. The study is reported according to the PRISMA 
checklist (12). 
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Results 
A total of 1,382 potentially relevant citations were identified (PubMed: 636, EMBASE: 508, 
Cochrane Central Register of Controlled Trials: 130, Centre for Evidence in Transplantation 
Library: 108). Following review of titles and abstracts and removal of duplicate publications, 
42 potentially eligible articles were identified. Ten trials, including a total of 1,927 
randomised patients, were selected for inclusion in the meta-analysis (Figure 1). Two 
randomised controlled trials were excluded: the study reported by Herlenius et al because it 
evaluated conversion from CNI to either sirolimus or mycophenolate mofetil without 
inclusion of a reference arm (13); and the study reported by Asrani et al because it evaluated 
de novo rather than delayed use of sirolimus, and reduction rather than cessation of 
tacrolimus (10). 
All included studies were designed to evaluate the safety and efficacy of conversion from 
CNI to mTORi immunosuppression in adult liver transplant patients. Study design 
characteristics, immunosuppression regimens and reported outcomes for each trial are 
summarized in Table S2. The median sample size was 112 participants (IQR 41-271) and the 
median treatment duration was 12 months (min 12 months, max 72 months). All studies 
reported renal function, acute rejection, graft loss, patient survival and adverse events. Renal 
function was measured by radionuclide method in one trial (14) and estimated using 
Cockcroft-Gault (15-20), Chronic Kidney Disease Epidemiology Collaboration (21, 22) and 
MDRD formulae (23, 24) in the remaining studies (25, 26). Early conversion to mTORi 
(defined as ≤6 months after transplantation) was evaluated in 4 studies (16, 17, 21, 25), 
whereas 6 studies evaluated late conversion to mTORi (14, 15, 18-20, 26). Five studies, 
including 943 participants, examined conversion from CNI to everolimus (17, 20, 21, 25, 26), 
whereas the remaining 5 studies, including 984 participants, evaluated conversion from CNI 
to sirolimus (14-16, 18, 19). There was variation in baseline renal function, both within and 
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between studies, but the majority of patients had mild or moderate renal dysfunction at the 
time of randomisation (CKD stage II or III). 
The risk of bias was evaluated using the Cochrane’s Collaboration tool (Table S3). Allocation 
sequence generation was described in 9 studies, but allocation concealment was clearly 
reported only by Watson et al (14). Eight studies were open-label, whereas 2 studies did not 
report blinding parameters. Attrition was adequately reported in all studies and was generally 
low (<20%) and intention-to-treat analyses were reported in all trials. Table S5 shows the 
proportion of patients that failed to be randomised or discontinued the allocated treatment, for 
each study. At the meta-analysis level, there was no indication of small study effects, based 
on either funnel plot asymmetry or the Begg-Mazumbar statistic; we acknowledge that this 
conclusion is based on a limited number of studies. 
Assessed outcomes and evidence synthesis 
Renal function 
Renal function at 1 year following randomisation was reported by all included studies. 
Because of variability in the reporting of this outcome (six studies reported GFR estimates 
whereas four studies reported CrCl measurements/estimates; Table S2), the standardised 
mean difference (SMD) between the mTORi and the CNI groups was calculated. In the ITT 
analysis, patients converted to mTORi had significantly better renal function at 1 year 
following randomisation compared to patients remaining on CNI (SMD: 0.40, 95% CI: 0.17-
0.63, I2: 78%; Figure 2A). Transformation of SMD into the GFR scale corresponded to a 
mean difference of 7.48 mL/min/1.73m2 (95% CI: 3.18-11.8) between the two groups. When 
studies were stratified according to time of conversion to mTORi (early versus late 
conversion, defined as ≤6 months after transplantation), there was a non-statistically 
significant trend towards a more favourable GFR difference between mTORi and CNI groups 
in the early conversion trials (SMD: 0.53, 95% CI: 0.28-0.77, I2: 69%) compared to late 
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conversion trials (SMD: 0.22, 95% CI: -0.06 to 0.49, I2: 52%), with reduction in 
heterogeneity only for late conversion trials (Figure 2B). Trial stratification according to 
mTORi type (sirolimus versus everolimus) showed no significant subgroup differences 
(SMD: 0.44, 95% CI: 0.16-0.71, I2: 70% for everolimus conversion trials versus SMD: 0.37, 
95% CI: -0.04 to 0.77, I2: 81% for sirolimus conversion trials; Figure 2C). 
To further address heterogeneity for renal function at 1 year following conversion to mTORi, 
sensitivity analyses were performed excluding 2 trials evaluating CNI minimisation in the 
reference group (20, 25) or steroid elimination regimens (25). Overall, there was no change in 
heterogeneity compared to the original meta-analysis (SMD: 0.35, 95% CI: 0.12-0.58, 
I2: 74% for GFR at 1 year). A recent study indicated that estimation of GFR using the MDRD 
formula may lead to incorrect interpretation of renal function in liver transplant patients; we 
have, therefore, performed additional sensitivity analysis excluding 2 trials that reported GFR 
estimates based on MDRD (25, 26) and a similar effect to the original meta-analysis was 
observed (SMD: 0.31, 95% CI: 0.09-0.53, I2: 74%). Moreover, meta-regression analyses 
accounting for baseline GFR or CrCl estimates, showed that baseline renal function had no 
significant effect on the difference in renal function between mTORi and CNI groups at 1 
year following randomisation (data not shown). 
Acute rejection 
All included studies contributed to the meta-analysis evaluating the association between 
conversion from CNI to mTORi based immunosuppression and acute liver allograft rejection 
(Table S4). All studies used the definition of biopsy proven acute rejection (BPAR) except 
those by Eisenberger et al and Shenoy et al (15, 19). Conversion to mTORi compared to CNI 
maintenance was associated with higher risk of reported acute rejection up to one year post-
randomisation (RR: 1.76, 95% CI: 1.33-2.34, I2: 0%; Figure 3). Analysis based on a 
definition of BPAR showed similar findings (RR: 1.77, 95% CI: 1.33-2.36, I2: 0% for patients 
converted to mTORi). There was a higher risk of acute rejection following conversion to 
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mTORi both in sirolimus conversion trials (RR: 2.19, 95% CI: 1.36-3.54, I2: 0%) and 
everolimus conversion trials (RR: 1.57, 95% CI: 1.10-2.23, I2: 0%) and overall, subgroup 
analyses did not reveal statistically significant differences between subgroups (data not 
shown). 
Liver allograft loss and mortality 
Three studies contributed to the meta-analysis evaluating the association between conversion 
from CNI to mTORi based immunosuppression and liver allograft loss (16, 17, 21), whereas 
in the remaining seven studies none of the liver allografts were lost within the first year post-
randomisation (graft loss was censored for patient death with the exception of the Spare the 
Nephron study that reported a composite outcome of death and graft loss) (14, 15, 18-20, 25, 
26). Patients converted to mTORi had similar risk of allograft loss compared to patients 
remaining on CNI (RR: 0.77, 95% CI: 0.29-2.09, I2: 31%; excluding the Spare the Nephron 
trial did not change the RR significantly but eliminated heterogeneity). Overall, 12 patients in 
the mTORi group and 17 patients in the CNI group lost their graft within the first year post-
randomisation. There were no reported allograft losses in late conversion trials but the data 
were too sparse to allow for sensitivity or meta-regression analyses. 
All studies reported mortality up to 1 year post-randomisation. Overall, 38 (3.6%) patients in 
the mTORi group and 29 (3.4%) patients in the CNI group died within the first year post-
randomisation. There were no differences in mortality between patients converted to mTORi 
and those remaining on CNI (RR: 1.05, 95% CI: 0.63-1.73, I2: 0%). Risk ratios and 
heterogeneity were similar when trials were stratified according to time of conversion to 
mTORi or according to mTORi type. 
Adverse events 
Adverse events were reported by all studies included in the meta-analysis, although there 
were differences between studies in the nature and incidence of the reported adverse events. 
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The risk of study discontinuation due to adverse events up to 1 year post-randomisation was 
greater in patients converted to mTORi than in patients remaining on CNI (RR: 2.17, 95% 
CI: 1.38-3.44, I2: 63%; Figure 4). Stratification by time of conversion showed that the risk of 
study discontinuation following conversion to mTORi was statistically significantly higher in 
late conversion trials (RR: 5.02, 95% CI: 2.91-8.68, I2: 0%) compared to early conversion 
trials (RR: 1.57, 95% CI: 1.14-2.15, I2: 42%). Risk ratios and heterogeneity did not change 
significantly if trials were stratified according to type of mTORi. Sensitivity analyses showed 
similar risk ratios for the overall and subgroup analyses but eliminated heterogeneity for early 
conversion trials (RR: 1.71, 95% CI: 1.34-2.17, I2: 0%) and everolimus conversion trials (RR: 
1.98, 95% CI: 1.45-2.71, I2: 0%). 
Reported adverse events along with risk ratio estimates and 95% CI up to one year post-
randomisation are summarised in Figure 5. Compared to patients on CNI continuation, those 
converted to mTORi had a higher risk of hyperlipidaemia (4.7% and 26.5% respectively; RR: 
4.81, 95% CI: 3.06-7.55, I2: 0%); hypercholesterolaemia (4.9% and 22.8% respectively; RR: 
4.18, 95% CI: 1.79-9.75, I2: 57%); requirement for new statin therapy (7.4% and 16.1% 
respectively; RR: 1.77, 95% CI: 0.65-4.86, I2: 8%); skin rash (3.4% and 23.1% respectively; 
RR: 5.58, 95% CI: 3.45-9.02, I2: 0%); mouth ulceration (0.7% and 13.3% respectively; RR: 
10.18, 95% CI: 4.26-24.33, I2: 0%); proteinuria (1.0% and 4.1% respectively; RR: 3.19, 95% 
CI: 1.40-7.28, I2: 0%); and oedema (9.0% and 20.1% respectively; RR: 2.08, 95% CI: 1.58-
2.74, I2: 0%). There was a non-statistically significant trend towards higher risk of infections 
in the mTORi conversion group (47.4%, compared to 38.0% of patients maintained on CNI; 
RR: 1.18, 95% CI: 0.98-1.43, I2: 52%). Patients converted to mTORi had a lower risk of 
requiring renal replacement therapy (RR: 0.48, 95% CI: 0.21-1.11, I2: 19%) that did not reach 
statistical significance. Heterogeneity was significant for studies reporting 
hypercholesterolaemia and this was eliminated for the three studies (17, 20, 26) evaluating 
conversion to everolimus (RR: 2.51, 95% CI: 1.39-4.54, I2: 0%). Similarly, subgroup 
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analyses for infections showed similar risk ratios to the pooled analysis but heterogeneity was 
eliminated for everolimus and late conversion trials (data not shown). 
Longer term outcomes 
Longer term renal function (>1 year) was reported by only two of the included trials. The 
H2304 study showed that patients converted to mTORi had significantly higher renal 
function at 3 years following randomisation compared to patients remaining on CNI (ITT 
analysis, MD: 17.0 mL/min/1.73m2, 95% CI: 13.5-20.6) (27); a similar trend was reported for 
an ‘on-treatment’ population by the PROTECT study at 3 years follow up (MD: 6.9 
mL/min/1.73m2, 95% CI: 1.7-12.3) (28). No differences were reported between patients 
remaining on CNI and those converted to mTORi in the three studies reporting allograft loss 
(18, 27, 28) and the two studies reporting patient death (27, 28) 3 years following 
randomisation (data not shown).
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Discussion 
The findings from this systematic review and meta-analysis of RCTs show that conversion 
from CNI to mTORi-based maintenance immunosuppression after liver transplantation is 
associated with a significant improvement in renal function at 12 months following 
conversion. Graft and patient survival were equivalent in patients converted to mTORi and 
those remaining on CNI, but recipients converted to mTORi had a higher risk of acute graft 
rejection. Moreover, discontinuation due to adverse events was more commonly observed in 
patients converted to mTORi. 
A previous meta-analysis published in 2010 evaluated the use of sirolimus in patients with 
renal impairment after liver transplantation and concluded that conversion to mTORi was 
associated with a non-significant trend towards improved renal function (29). While several 
observational studies were assessed, only three RCTs (including a total of 86 patients) were 
available at that time for inclusion in the analysis (14, 15, 19). In the present study a further 
seven RCTs (2 evaluating sirolimus and 5 evaluating everolimus) were available for analysis 
(giving a total of 1,927 patients) enabling a more robust, direction-consistent estimate of the 
effect of CNI discontinuation on renal function. Given the observed marked heterogeneity 
(I2: 78%) for trials reporting on the effect of mTORi conversion on renal function, caution is 
required with respect to the magnitude of the overall estimate for this outcome. Subgroup and 
sensitivity analyses reinforced the overall conclusion that conversion to mTORi was 
associated with improved renal function but did not eliminate heterogeneity. The present 
analysis showed that conversion to mTORi did not have an adverse effect on graft or patient 
survival compared to CNI continuation and minimal heterogeneity was observed for these 
outcomes. 
It has been reported that conversion to mTORi and discontinuation of CNI without adequate 
antibody induction therapy increases the risk of acute rejection (17, 21). The present meta-
analysis showed that conversion to mTORi is associated with a higher risk of acute rejection 
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although the cumulative sample size cannot support a well-powered subgroup analysis. 
Nevertheless in one of the studies the study arm examining conversion to everolimus and 
CNI elimination was discontinued because of a high incidence of biopsy proven acute 
rejection (21). While the present analysis did not show a difference in acute rejection between 
trials evaluating abrupt and tapered discontinuation of CNI, it has been suggested that tapered 
discontinuation is preferable, especially when mTORi conversion is introduced within the 
first few months of liver transplantation (17). CNI minimisation is an alternative strategy to 
CNI withdrawal after conversion to mTORi and may allow preservation of renal function 
without compromising efficacy of immunosuppression (30). Two of the RCTs included in the 
present analysis adopted this approach, one of which reported superior GFR in the mTORi 
group whereas the other showed equivalent renal function after one year (20, 25).  Experience 
in renal transplantation suggests that there is enhanced nephrotoxicity when CNIs are 
combined with mTORi (31-33). 
There is currently a trend towards early (≤6 months after transplantation) rather than late 
conversion to mTORi after liver transplantation before residual kidney function deteriorates 
and chronic kidney disease is established. Three out of the five most recent RCTs included in 
the present analysis evaluated early conversion to everolimus (the earliest being conversion at 
10 days) and included recipients with relatively high baseline estimated GFR. Our meta-
analysis showed that early versus late conversion to mTORi was associated with a trend 
towards better renal function at twelve months; however, our analysis was underpowered to 
exhibit a robust subgroup difference and, therefore, the evidence for the optimal time for 
conversion to mTORi is inconclusive. Nevertheless, it is notable that every one of the early 
conversion trials showed a statistically significant improvement in renal function 12 months 
after conversion to mTORi, whereas five out of the six trials evaluating late conversion to 
mTORi did not show a statistically significant difference in 12-month renal function between 
the CNI and mTORi groups. 
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Mammalian target of rapamycin inhibitors are associated with a number of well described 
side effects that may limit the ability of patients to tolerate them (8, 34, 35). Our analysis 
confirmed this, indicating that the risk of study discontinuation following mTORi conversion 
was twice that of patients maintained on CNIs and trial withdrawal due to adverse events was 
more likely after late conversion to mTORi. Withdrawal rates in patients converted to mTORi 
varied widely between RCTs from only 5% to as high as 55%. Overall, there was a 
substantial risk of adverse events following conversion to mTORi and this represents a 
significant barrier for their utility in preserving renal function after liver transplantation. 
Specifically, our analyses showed that conversion to mTORi is associated with an increased 
risk of hyperlipidaemia and hypercholesterolaemia, although the requirement for new statin 
therapy was not different to patients maintained on CNI. Limited data from retrospective 
studies suggested a beneficial effect of conversion to mTORi on management of hypertension 
(36), however, there was insufficient high-quality evidence to examine this association in our 
study. Conversion to mTORi also increased the risk of dermatological adverse events and 
mouth ulceration, but the rate of infections was similar to that of patients receiving CNI 
maintenance. Pooled analysis from two early and one late conversion trials did not confirm 
the known association of mTORi with poor wound healing. A significant drawback of 
treatment with mTORi is the development of proteinuria which may reach the nephrotic 
range, especially following exposure to high sirolimus concentrations (37); our analysis 
confirmed this association, although the reported proteinuria levels were usually mild or less 
often moderate whereas development of nephrotic range proteinuria was rare and occurred in 
the presence of significant pre-existing renal injury. 
The majority of RCTs included in our meta-analysis were not powered to detect a difference 
in graft or patient survival and given the high rate of study withdrawals reported, the true 
effect of mTORi conversion on graft and patient outcomes is still to some extent uncertain. 
This is especially the case for long-term outcomes, given that only three of the ten studies 
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included in the meta-analysis reported outcomes beyond one year. Evidence from 
retrospective analyses suggest that sirolimus immunosuppression is associated with a 
significant graft and patient survival benefit after liver transplantation for hepatocellular 
carcinoma (38-40); only two trials examined outcomes following mTORi conversion in this 
subgroup of patients and, compared to patients maintained on CNI, reported a non-significant 
reduction in disease recurrence in the everolimus group (25) and significantly better 
graft/patient survival in the sirolimus group (16). Both studies, however, were underpowered 
to examine outcomes in patients undergoing liver transplantation for hepatocellular 
carcinoma and strong evidence on the utility of mTORi in this subgroup of patients is still 
lacking. Similarly, the evidence from cohort studies regarding the effect of mTORi on 
hepatitis C recurrence and fibrosis progression in patients undergoing liver transplantation for 
hepatitis C related cirrhosis is equivocal (36, 41, 42); although the study by Villamil et al (26) 
suggested that conversion to everolimus reduces liver fibrosis progression, further large 
randomised-controlled trials are needed to provide clear evidence as to optimal 
immunosuppression in this group of patients. 
It is important to acknowledge some additional limitations of the present meta-analysis. 
Publication and language bias may be operating in any clinical field; however, the 
comprehensive search algorithm utilised herein, including the Cochrane Controlled Trials 
Registry and the Transplant Library at the RCSEng that are built from multiple large 
databases, enhanced the detection of smaller trials and we would, therefore, expect that 
incorporation of any unpublished evidence would not substantially alter the overall status of 
the evidence. This notion was supported by the observed consistency of the reported 
summary effects in small studies. Moreover, although randomised evidence is protected from 
selection bias, performance and detection bias could be potential confounders. An approach 
towards addressing this would be to exclude open-label studies. Unfortunately, all included 
studies were, by necessity, open-label trials and, therefore, trial exclusion was not an 
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available option. Finally, a number of study parameters could potentially interfere with our 
study results. The inclusion of trials examining conversion to either sirolimus or everolimus 
utilising heterogeneous treatment algorithms; the variation in baseline renal function between 
studies; and the distinct patient characteristics within individual trials might have contributed 
to the observed heterogeneity. Nevertheless, the all-inclusiveness and randomised nature of 
the analysed evidence limits potential sources of bias; alternative research designs, such as 
individual patient data meta-analysis, which may further address confounding lie beyond the 
scope of the present study. 
In conclusion, the currently available randomised evidence indicates that conversion from 
CNI to mTORi following liver transplantation is associated with improved renal function at 
12 months and this benefit is likely to be more pronounced when conversion occurs early 
after transplantation before irreversible kidney injury is established. In deciding the optimal 
immunosuppression strategy for their patients, clinicians should be alert to the increased risk 
of acute rejection following conversion to mTORi which is, however, treatable and has no 
effect on short-term graft and patient outcomes. Conversion to mTORi, especially when 
attempted late after transplantation, may be poorly tolerated and careful patient selection is 
important to maximise the benefits of this intervention. No firm conclusions can be drawn 
about the relative efficacy of different mTORi, and the relative advantages of CNI 
minimisation versus discontinuation. 
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Figure Legends 
Figure 1. Flowchart of included studies 
Abbreviations: EMBASE, Excerpta Medica Database; CNI, Calcineurin Inhibitor; mTOR, 
mammalian Target of Rapamycin; RCT, randomised controlled trial. 
Figure 2A: Mammalian target of rapamycin inhibitor versus calcineurin inhibitor; 
mean GFR up to 1 year post-randomisation 
Figure 2B: Mammalian target of rapamycin inhibitor versus calcineurin inhibitor; 
mean GFR up to 1 year post-randomisation stratified by time post-transplant 
Figure 2C: Mammalian target of rapamycin inhibitor versus calcineurin inhibitor; 
mean GFR up to 1 year post-randomisation stratified by type of mammalian target of 
rapamycin inhibitor sirolimus and everolimus 
Abbreviations: GFR, Glomerular Filtration Rate; CNI, Calcineurin Inhibitor; mTOR, 
mammalian Target of Rapamycin 
*5 patients in the mTOR inhibitor arm and 4 patients in the CNI arm of this study were 
excluded from the initial randomised population (by the authors of the study) because of 
missing post-baseline GFR data (forming the intention-to-treat population) 
**1 patient randomised to receive mTOR inhibitor was excluded from the intention-to-treat 
analysis (by the authors of the study) because they did not receive the allocated intervention 
after randomisation 
Figure 3. Mammalian target of rapamycin inhibitor versus calcineurin inhibitor; any 
rejection up to 1 year post-randomisation 
Abbreviations: CNI, Calcineurin Inhibitor; mTOR, mammalian Target of Rapamycin 
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*5 patients in the mTOR inhibitor arm and 4 patients in the CNI arm of this study were 
excluded from the initial randomised population (by the authors of the study) because of 
missing post-baseline GFR data (forming the intention-to-treat population) 
**1 patient randomised to receive mTOR inhibitor was excluded from the intention-to-treat 
analysis (by the authors of the study) because they did not receive the allocated intervention 
after randomisation 
Figure 4. Mammalian target of rapamycin inhibitor (mTORi) versus calcineurin 
inhibitor (CNI); adverse events up to 1 year post-randomisation leading to study 
discontinuation 
The safety population analysis is reported (all eligible studies reported adverse events for the 
safety population defined as the total number of patients that received at least one dose of the 
allocated intervention). Abbreviations: CNI, Calcineurin Inhibitor; mTOR, mammalian 
Target of Rapamycin 
*4 patients in each arm of this study were excluded from the initial randomised population 
(by the authors of the study) because they did not receive the allocated intervention after 
randomisation 
**1 patient in the mTOR inhibitor arm and 2 patients in the CNI arm of this study were 
excluded from the initial randomised population (by the authors of the study) because they 
did not receive the allocated intervention after randomisation 
***1 patient in the mTOR inhibitor arm did not receive the allocated intervention after 
randomisation but was included in the safety population of the CNI arm (by the authors of the 
study) because the patient had been receiving CNI prior to randomisation 
Figure 5. Pooled risk ratio estimates and 95% confidence intervals for adverse events up 
to 1 year following conversion to mammalian target of rapamycin inhibitor 
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*All studies reported graft loss censored for patient death apart from the Spare the Nephron 
study that reported a composite outcome of death and graft loss; excluding the Spare the 
Nephron trial did not change the risk ratio for graft loss significantly. 
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